Evidence map›Paper›PMID 42493791›Full record

ArticleStem cell research & therapy2026

Intravenous placenta-derived mesenchymal stem cells enhance early survival as an adjunct to supportive care in severe burn: a preclinical study.

Eng-Kean Yeong, Houng-Chi Liou, Yan Ting Liou, Chin-Hao Chang, Yu-Xiu Lin, Thai-Yen Ling

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eng-Kean YeongDivision of Plastic Surgery, Department of Surgery, National Taiwan University Hospital, No. 7, Chung Shan South Road, Taipei, 100, Taiwan. smartpace88@gmail.com.
Houng-Chi Liou *Department of Pharmacology, College of Medicine, National Taiwan University, No. 1 Jen Ai Road Section 1, Taipei, 100, Taiwan.
Yan Ting Liou *Division of Plastic Surgery, Department of Surgery, National Taiwan University Hospital, No. 7, Chung Shan South Road, Taipei, 100, Taiwan.
Chin-Hao Chang *Department of Medical Research, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.
Yu-Xiu Lin *Department of Pharmacology, College of Medicine, National Taiwan University, No. 1 Jen Ai Road Section 1, Taipei, 100, Taiwan.
Thai-Yen LingDepartment of Pharmacology, College of Medicine, National Taiwan University, No. 1 Jen Ai Road Section 1, Taipei, 100, Taiwan. tyling@ntu.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere burn injury induces a rapid systemic inflammatory response, and early survival depends heavily on timely fluid resuscitation and thermal support. However, optimal supportive care may be difficult to deliver in austere or resource-limited environments. Placenta-derived choriodecidual mesenchymal stem cells (pcMSCs) possess immunomodulatory properties and may improve outcomes when supportive care is suboptimal. This study investigated whether intravenous pcMSC therapy improves early survival after severe burn injury in a preclinical model.

methodsSixty adult male Sprague-Dawley rats underwent standardized 40% total body surface area full-thickness burns and were randomly assigned to six groups (n = 10/group) differing in fluid resuscitation (1× vs. 3× Ringer's lactate), thermal support (heating lamp vs. incubator warming), and intravenous pcMSC therapy. Survival was monitored for 14 days and analyzed using Kaplan-Meier methods with log-rank testing. Serum TNF-α, IL-1β, and IL-6 levels, body weight, water intake, and core body temperature were assessed longitudinally in selected groups.

resultsSurvival differed significantly among groups, with 93% of deaths occurring within the first 3 days post-burn. Under low-volume resuscitation, survival declined to 30% in untreated animals and improved to 50% with pcMSC therapy, indicating a survival benefit under insufficient resuscitation conditions. With adequate fluid resuscitation and thermal support, survival was high without pcMSCs (80%) and numerically higher with pcMSCs (90%), although this difference was not statistically significant after adjustment. Thermal support exerted a marked effect on outcomes, with warmed animals demonstrating substantially higher survival despite similar or lower fluid volumes. PcMSC treatment attenuated post-burn hypothermia, reduced weight loss and dehydration, and significantly decreased circulating TNF-α, IL-1β, and IL-6 levels.

conclusionsPlacenta-derived choriodecidual mesenchymal stem cells may confer an additive survival benefit after severe burn injury, particularly under inadequate fluid resuscitation and thermal support, likely through stabilization of body temperature, improved hydration, and attenuation of systemic inflammation, supporting their potential role as an adjunctive therapy in austere or resource-limited settings.

Indexed as

BurnsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationPlacentaAnimalsDisease Models, AnimalFemaleFluid TherapyInterleukin-6MalePregnancyRatsRats, Sprague-DawleyTumor Necrosis Factor-alphaInterleukin-6Tumor Necrosis Factor-alphaAustere environmentsPlacenta-derived MSCsSevere burnsSurvival

Identifiers

PMID42493791
PMCPMC13397731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.